368 related articles for article (PubMed ID: 19000370)
1. Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase.
Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Yang H
J Pharm Pharmacol; 2008 Dec; 60(12):1651-7. PubMed ID: 19000370
[TBL] [Abstract][Full Text] [Related]
2. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
3. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
4. Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats.
Ma Y; Yang Q; Wang L; Zhou X; Zhao Y; Deng Y
Eur J Pharm Sci; 2012 Apr; 45(5):539-45. PubMed ID: 22155543
[TBL] [Abstract][Full Text] [Related]
5. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
6. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes.
Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 354(1-2):56-62. PubMed ID: 18083313
[TBL] [Abstract][Full Text] [Related]
7. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes.
Koide H; Asai T; Hatanaka K; Akai S; Ishii T; Kenjo E; Ishida T; Kiwada H; Tsukada H; Oku N
Int J Pharm; 2010 Jun; 392(1-2):218-23. PubMed ID: 20227473
[TBL] [Abstract][Full Text] [Related]
8. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes.
Ishida T; Ichihara M; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):243-50. PubMed ID: 17011060
[TBL] [Abstract][Full Text] [Related]
9. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs.
Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Ishihara H; Kikuchi H
Int J Pharm; 2012 Oct; 436(1-2):636-43. PubMed ID: 22850293
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection.
Laverman P; Carstens MG; Boerman OC; Dams ET; Oyen WJ; van Rooijen N; Corstens FH; Storm G
J Pharmacol Exp Ther; 2001 Aug; 298(2):607-12. PubMed ID: 11454922
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.
Amantea MA; Forrest A; Northfelt DW; Mamelok R
Clin Pharmacol Ther; 1997 Mar; 61(3):301-11. PubMed ID: 9084455
[TBL] [Abstract][Full Text] [Related]
12. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy.
Li C; Cui J; Wang C; Li Y; Zhang H; Wang J; Li Y; Zhang L; Zhang L; Guo W; Wang Y
Eur J Pharm Biopharm; 2008 Oct; 70(2):657-65. PubMed ID: 18582570
[TBL] [Abstract][Full Text] [Related]
13. Pegylated liposomal doxorubicin in ovarian cancer.
Green AE; Rose PG
Int J Nanomedicine; 2006; 1(3):229-39. PubMed ID: 17717964
[TBL] [Abstract][Full Text] [Related]
14. Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan.
Li C; Zhao X; Wang Y; Yang H; Li H; Li H; Tian W; Yang J; Cui J
Int J Pharm; 2013 Feb; 443(1-2):17-25. PubMed ID: 23318366
[TBL] [Abstract][Full Text] [Related]
15. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
[TBL] [Abstract][Full Text] [Related]
16. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin.
Song H; Zhang J; Han Z; Zhang X; Li Z; Zhang L; Fu M; Lin C; Ma J
Cancer Chemother Pharmacol; 2006 May; 57(5):591-8. PubMed ID: 16133530
[TBL] [Abstract][Full Text] [Related]
18. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
19. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species.
Li C; Cao J; Wang Y; Zhao X; Deng C; Wei N; Yang J; Cui J
J Pharm Sci; 2012 Oct; 101(10):3864-76. PubMed ID: 22777607
[TBL] [Abstract][Full Text] [Related]
20. Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity.
Charrois GJ; Allen TM
J Pharmacol Exp Ther; 2003 Sep; 306(3):1058-67. PubMed ID: 12808004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]